Olanzapine and Weight Loss in Early-Onset Schizophrenia

Ahmed Naguy, MBBch, MSc^a; Bibi Alamiri, MD, ABPN, ScD^a,f,g; Anubhuti Singh, MBBch, MD, MRCPsych^d,e; Saxby Pridmore, MD, FRANZCP^c; Reda Rushdy, MD, PhD^b

Prim Care Companion CNS Disord 2023;25(2):21cr03113

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

References (14)

Naguy A, El-Sori D. Metformin for antipsychotic-related metabolic syndrome in children: fact or fiction? Chin Med J (Engl). 2018;131(12):1490–1491. PubMed CrossRef
Naguy A, Moodliar-Rensburg S, Alamiri B. Clozapine-associated hypothyroidism. Am J Ther. 2020;28(6):e722–e724. PubMed CrossRef
Tungaraza TE. Significant weight loss following clozapine use, how is it possible? a case report and review of published cases and literature relevant to the subject. Ther Adv Psychopharmacol. 2016;6(5):335–342. PubMed CrossRef
Naguy A, Roshdy R, Al-Mutairi A, et al. Mirtazapine improved eating patterns in avoidant/restrictive food intake disorder. Am J Ther. 2023;30(2):173–175. PubMed CrossRef
Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry suppl. 1989;155(S7):49–58. PubMed CrossRef
Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247–251. PubMed CrossRef
Bush G, Fink M, Petrides G, et al. Catatonia, I: rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129–136. PubMed CrossRef
Naguy A, Roshdy R, Al-Mutairi A, et al. Mirtazapine improved eating patterns in avoidant/restrictive food intake disorder. Am J Ther. 2021;Publish Ahead of Print. PubMed CrossRef
Alphs L, Morlock R, Coon C, et al. The 4-Item Negative Symptom Assessment (NSA-4) Instrument: a simple tool for evaluating negative symptoms in schizophrenia following brief training. Psychiatry (Edgmont). 2010;7(7):26–32. PubMed
Naguy A. Levomilnacipran for negative symptom domain schizophrenia. Prim Care Companion CNS Disord. 2021;23(6):20I02873. PubMed CrossRef
Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia: a 1 year open-label, prospective trial. Hum Psychopharmacol. 2008;23(3):211–216. PubMed CrossRef
Naguy A, Rushdy R, Pridmore S, et al. Successful add-on viloxazine to clozapine-responsive schizophrenia mitigated cognitive, negative and metabolic domains. Psychopharmacol Bull. 2022;52(1):57–60. PubMed
Moodliar S, Naguy A, Elsori DH. Add-on mirtazapine to clozapine-responsive early-onset schizophrenia. Psychiatry Res. 2020;284:112701. PubMed CrossRef
Naguy A. Stimulants use in attention-deficit/hyperactivity disorder (ADHD) kids: triumph or tribulation? J Can Acad Child Adolesc Psychiatry. 2016;25(3):136–137. PubMed